中国医院用药评价与分析Issue(12)：1083-1085,3.DOI:10�14009/j.issn.1672-2124.2014.12.009
注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合柳氮磺吡啶治疗强直性脊柱炎的临床观察
Clinical Efficacy of Recombinant Human Interferon Type Ⅱ Tumor Necrosis Factor Receptors for Injection plus Sulfasalazine for Ankylosing Spondylitis
王守赟 1阮文礼 1宋子缨1
作者信息
- 1. 大连市第二人民医院骨科，辽宁大连 116011
- 折叠
摘要
Abstract
OBJECTIVE:To explore the clinical efficacy of recombinant human interferon type Ⅱ tumor necrosis factor receptors plus sulfasalazine for ankylosing spondylitis. METHODS:100 patients with ankylosing spondylitis in our hospital from January 2012 to January 2014 were randomly divided into control group and experimental group, with control group given sulfasalazine alone and the experimental group given etanercept plus sulfasalazine for 3 months( a course of treatment ) . RESULTS: After treatment of one course, both groups showed reduction in BASDAI score, degree of joint swelling, duration of morning stiffness, erythrocyte sedimentation rate and C⁃reactive protein;however, the patients in the experimental group showed better clinical remission than in the control group and the difference between the two groups was significant(P<0�05); the total effective rate in the experimental group was significantly higher than in the control group [ 94%( 47/50 ) vs. 70%( 35/50 ) ] and the difference between the two groups was significant ( P <0�05 ) . CONCLUSIONS: Etanercept plus sulfasalazine showed remarkable efficacy for ankylosing spondylitis, which thus is worthy of popularization in clinical application.关键词
强直性脊柱炎/注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白/柳氮磺吡啶Key words
Ankylosingspondylitis/Recombinant human interferon typeⅡtumor necrosis factor receptors/Sulfasalazine分类
医药卫生引用本文复制引用
王守赟,阮文礼,宋子缨..注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合柳氮磺吡啶治疗强直性脊柱炎的临床观察[J].中国医院用药评价与分析,2014,(12):1083-1085,3.
